Pulse Biosciences, INC.: management transactions · United States · SEC (Form 4)

About Pulse Biosciences, INC.

Pulse Biosciences, Inc. is a United States-based medical technology and bioelectric medicine company listed on the Nasdaq market under the ticker PLSE. The company focuses on non-thermal ablation technologies and is built around its proprietary nPulse™ platform, which uses Nanosecond Pulsed Field Ablation (nsPFA™) energy to deliver extremely short electrical pulses intended to target cells while sparing adjacent non-cellular tissue. In investor materials and company filings, Pulse Biosciences positions itself as a developer of novel therapeutic solutions for areas where current treatment options remain incomplete or suboptimal. ([investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/?utm_source=openai)) Founded in 2014, the company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. That corporate transition reflects a broader strategic evolution from an early-stage technology developer into a clinical-stage medtech platform company. Over time, the business has sharpened its focus on higher-value healthcare applications, particularly atrial fibrillation, while still maintaining optionality in other soft-tissue ablation use cases. ([stockanalysis.com](https://stockanalysis.com/stocks/plse/company/?utm_source=openai)) Pulse Biosciences’ product portfolio is centered on several nPulse-branded systems. The CellFX System is described by the company as its first commercial product based on Nano-Pulse Stimulation (NPS™) technology. Beyond that, the company is advancing the nPulse Vybrance Percutaneous Electrode System, the nPulse Cardiac Surgical Clamp, the nPulse Cardiac Catheter System, and the nPulse Console platform. Together, these programs suggest a strategy of expanding from dermatologic or soft-tissue applications into cardiac electrophysiology, where the clinical and commercial opportunity is materially larger but also more demanding from a regulatory and execution standpoint. ([investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/?utm_source=openai)) From a competitive perspective, Pulse Biosciences occupies a niche position in a field dominated by larger medical device companies and established electrophysiology players. Its key differentiators are its patented nsPFA mechanism, its non-thermal approach, and its broad intellectual property portfolio. The company argues that these attributes may improve safety, preserve surrounding tissue, and potentially support better procedural outcomes compared with conventional thermal ablation methods. For investors, this makes PLSE a high-risk, high-upside development story rather than a mature commercial franchise. ([pulsebiosciences.com](https://www.pulsebiosciences.com/about-us/?utm_source=openai)) Recent developments have reinforced the company’s clinical momentum. In 2025 and early 2026, Pulse Biosciences issued multiple quarterly and annual business updates, presented early clinical data on its nPulse Cardiac Catheter program, and announced a research collaboration with The University of Texas MD Anderson Cancer Center to evaluate nsPFA for benign and malignant thyroid tumors. Those updates indicate a company that is still in the evidence-building phase, with future value likely to depend on clinical readouts, regulatory progress, and eventual physician adoption. The company remains headquartered in the United States and continues to communicate as a Nasdaq-listed medtech innovator with ambitions to scale its platform across multiple therapeutic areas. ([investors.pulsebiosciences.com](https://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-reports-business-updates-and-fourth-quarter-1?utm_source=openai))